Accuracy has always been the foundation. A CGM that underreports glucose affects treatment in real time.
When the tools we trust to keep us alive begin to lie, the consequences arrive without warning. A U.S. FDA safety alert linking certain Libre 3 continuous glucose monitors to seven deaths and over 700 serious injuries worldwide has reminded patients and physicians alike that technology, however precise, carries its own fragility. In India — home to more than 100 million people living with diabetes and a rapidly growing reliance on digital health devices — the alert has prompted specialists to reassure patients while raising harder questions about supervision, regulation, and the limits of the machines we wear on our skin.
- Faulty Libre 3 sensors displaying falsely low blood sugar readings have been linked to seven deaths and over 700 serious injuries globally, triggering an urgent FDA safety alert.
- For diabetics, a wrong glucose reading is not a minor error — it can trigger dangerous treatment decisions within minutes, from skipping insulin to eating unnecessary carbohydrates.
- India's 100+ million diabetics are adopting CGMs faster than medical oversight can follow, with many patients interpreting readings without doctor guidance and using devices that lack proper regulatory approval.
- Indian specialists have moved to calm fears, confirming that the implicated Libre 3 model is not available in India — but they warn that of nearly 20 glucometers on the Indian market, only four or five carry proper regulatory clearance.
- Doctors are urging patients to cross-check device readings against physical symptoms, revert to finger-prick testing when readings feel inconsistent, and treat the CGM as a tool — not an infallible authority.
A U.S. FDA safety alert has cast a long shadow over the world of diabetes care, after certain Libre 3 and Libre 3 Plus continuous glucose monitors were found to display dangerously false low blood sugar readings. Seven deaths and more than 700 serious injuries worldwide have been linked to these faulty sensors — a toll that speaks to how completely patients trust the small devices they wear on their skin to guide life-or-death decisions about insulin, food, and when to seek help.
For people with diabetes, a continuous glucose monitor is not a convenience — it is a lifeline. When its readings are wrong, the margin between safety and catastrophe can be measured in minutes. A falsely low reading can lead a patient to skip an injection, consume unnecessary carbohydrates, or delay emergency care, with consequences ranging from severe hyperglycemia to diabetic ketoacidosis.
India, home to over 100 million diabetics and a rapidly expanding digital health market, responded quickly. Leading specialists confirmed that Libre 3 has not been launched in India and that Indian patients are not exposed to the specific sensors under FDA scrutiny. But the alert opened a wider conversation. Dr. Rajiv Kovil noted that of nearly 20 glucometers available in Indian medical shops, only four or five carry proper regulatory approval — many are sold freely without adequate clearance from the FDA or India's Central Drugs Standard Control Organisation.
Dr. Vijay Negalur, drawing on 45 years of practice, reminded patients that accuracy has always been the foundation of diabetes care. If a device reading does not match how the body feels, he said, trust the body — and return to traditional finger-prick testing. Dr. Pranav Ghody echoed the reassurance about India's available models while stressing that technology transforms care without replacing it: regular medical follow-ups, bodily awareness, and knowing when to stop trusting the machine remain essential.
The alert is ultimately a reminder that in a country where digital health tools are proliferating faster than regulation can follow, safety depends not only on the device — but on the patient who knows what it is, whether it is approved, and when to set it aside.
A safety alert from the U.S. Food and Drug Administration has thrown a spotlight on a problem that touches millions of people who depend on technology to stay alive. Certain Libre 3 and Libre 3 Plus continuous glucose monitors—devices that track blood sugar in real time—have been displaying glucose readings that are dangerously, falsely low. The FDA has linked these faulty readings to seven deaths and more than 700 serious injuries worldwide, a toll that underscores how much trust patients place in the small sensors they wear on their skin.
For people with diabetes, a continuous glucose monitor is not a luxury. It is a lifeline. The devices deliver moment-to-moment glucose data through a smartphone app, allowing patients to see trends, adjust insulin doses, and make split-second decisions about food and activity. When those readings are wrong—especially when they tell a patient their blood sugar is lower than it actually is—the consequences can be swift and catastrophic. A falsely low reading might convince someone to skip an insulin injection, to eat carbohydrates they do not need, or to delay seeking help. The result can be severe high blood sugar, diabetic ketoacidosis, or the very hypoglycemia the device falsely warned about. The margin between safety and harm, in diabetes care, is often measured in minutes.
India is home to more than 100 million people living with diabetes, and the country has seen a sharp rise in the adoption of digital health tools like continuous glucose monitors. These devices promise convenience and precision—real-time data, trend analysis, the ability to monitor glucose levels far more frequently than traditional finger-prick testing allows. But this rapid adoption has outpaced the infrastructure of medical supervision. Many patients are using these devices without adequate oversight from a doctor, interpreting the readings themselves, and making treatment decisions based on data they may not fully understand. The risk of misinterpretation is real, and the stakes are high.
Indian diabetes specialists moved quickly to reassure patients in the wake of the FDA alert. Dr. Rajiv Kovil, head of diabetology at Zandra Healthcare, clarified that Libre 3 has not been launched in India. The faulty sensors under FDA scrutiny are not available to Indian patients. But Kovil also sounded a broader alarm about the devices that are available. Of the nearly 20 glucometers sold in the Indian market, he noted, only four or five have proper regulatory approval. Many devices are sold freely in medical shops without adequate clearance from authorities like the FDA or India's Central Drugs Standard Control Organisation. Patients, he urged, should consult their doctors before purchasing any glucose monitoring device and should rely only on equipment that has been vetted by regulatory bodies.
Dr. Vijay Negalur, head of diabetology at KIMS Hospitals in Thane, brought the weight of 45 years of practice to the conversation. Technology has evolved dramatically over his career, he said, but accuracy has always been the foundation of good diabetes care. A continuous glucose monitor that underreports glucose affects treatment in real time. If a reading does not match how a patient feels—if the device says the blood sugar is low but the person feels fine—the patient should trust their body and revert to traditional finger-prick testing. Batch details matter. Symptoms matter. The device is a tool, not an oracle.
Dr. Pranav Ghody, a consultant endocrinologist at Wockhardt Hospitals in Mumbai, reinforced the reassurance: Libre 2 and Libre 2 Plus are the models used in India, and neither is part of the FDA alert. But he also acknowledged a deeper truth. Technology has transformed diabetes care, but it is not infallible. Patients should verify their sensors, replace affected devices immediately if there is any doubt, and maintain the habits that kept people with diabetes alive before continuous monitors existed—regular follow-ups with doctors, awareness of their own bodies, listening to their symptoms. Safe diabetes management, he said, still requires all of these things. The device is part of the answer, not the whole answer.
The alert serves as a reminder that in a country where digital health tools are proliferating faster than regulation can keep pace, the burden of safety falls partly on patients themselves. Know what device you are using. Know whether it has been approved. Know what your body feels like. And know when to stop trusting the machine and trust yourself instead.
Citas Notables
Libre 3 has not been launched in India. Only Libre 2 and Libre 2+ are used here, and these models are not part of the FDA alert.— Dr. Pranav Ghody, consultant endocrinologist, Wockhardt Hospitals
In 45 years of practice, I have seen technology evolve dramatically, but accuracy has always been the foundation. If the reading doesn't match how you feel, trust your symptoms.— Dr. Vijay Negalur, head of diabetology, KIMS Hospitals
La Conversación del Hearth Otra perspectiva de la historia
Why does a faulty reading that shows low glucose matter more than one that shows high?
Because low glucose is immediately dangerous. A patient sees that number and thinks they need to eat or reduce insulin right now. They act on it. A high reading might prompt caution, but low glucose can trigger a cascade of decisions in minutes that lead to severe complications.
So the patient is essentially being told a lie that makes them treat themselves in the wrong direction.
Exactly. They're being told their blood sugar is crashing when it isn't. They consume carbohydrates they don't need, skip insulin they do need, delay medical help. The device is supposed to be the patient's eyes. When it lies, the patient is flying blind.
Why hasn't India banned these devices outright if they're faulty?
Because Libre 3 was never approved for sale in India in the first place. The alert is about a device that isn't here. But it exposed a bigger problem—many devices that are here don't have proper approval either. The market is moving faster than regulation.
What should a patient do if they're using a CGM and suddenly doubt it?
Check how they actually feel. If the device says low blood sugar but they feel fine, they should test with a traditional glucometer. If the readings don't match their symptoms, they should talk to their doctor immediately and consider going back to finger-prick testing until they're sure the device is reliable.
Is the issue that CGMs are bad, or that patients are using them without a doctor's guidance?
Both. The device itself failed in this case. But even a perfect device can be dangerous if a patient is interpreting it alone, without medical supervision. These tools need to be part of a relationship with a doctor, not a replacement for one.
What does this mean for the future of diabetes care in India?
It means the country needs to catch up. More devices will come. Patients will want them. But there needs to be clearer regulation, better approval processes, and a culture where patients understand that technology is a tool, not a substitute for medical judgment and self-awareness.